Medicine
Doxazosin 8 mg tablet
Doxazosin 8 mg tablet is a generic prescription medicine for oral use, made by 16 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Doxazosin
- Brand
- Sold under the generic name
- Strength
- 8 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets, 1000 tablets and 33 more
- Manufacturers
- Zydus LifesciencesIndiaUnichem LaboratoriesIndiaAccord HealthcareIndiaAurobindo PharmaIndiaAvet PharmaceuticalsIndiaAphena Pharma Solutions - TennesseeA-S Medication SolutionsApotexMylan PharmaceuticalsAvKARE
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C02CA04 Doxazosin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 October 2000
- Identifiers
- RxCUI 197628, 197625, 197626 +1DailyMed set ID 2e5cd8cb-7d43-e7af-e063-6294a90a310e, 2830533c-ccdf-4401-b19c-763eeb1bc0a7, e3d381c1-3b2f-af70-f4e6-08d6202eed25 +18NDC 71610-878, 16729-415, 42291-260 +18Application ANDA075580, ANDA202824, ANDA208719 +8
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 68382-786-01 | Zydus LifesciencesIndia | 31 August 2017 |
| 30 tablet in 1 bottle | 68382-786-06 | Zydus LifesciencesIndia | 31 August 2017 |
| 1000 tablet in 1 bottle | 68382-786-10 | Zydus LifesciencesIndia | 31 August 2017 |
| 10 blister pack in 1 carton / 10 tablet in 1 blister pack | 68382-786-77 | Zydus LifesciencesIndia | 31 August 2017 |
| 1000 tablet in 1 bottle | 70771-1115-0 | Zydus LifesciencesIndia | 31 August 2017 |
| 100 tablet in 1 bottle | 70771-1115-1 | Zydus LifesciencesIndia | 31 August 2017 |
| 30 tablet in 1 bottle | 70771-1115-3 | Zydus LifesciencesIndia | 31 August 2017 |
| 10 blister pack in 1 carton / 10 tablet in 1 blister pack | 70771-1115-4 | Zydus LifesciencesIndia | 31 August 2017 |
| 100 tablet in 1 bottle | 16729-415-01 | Accord HealthcareIndia | 10 July 2017 |
| 1000 tablet in 1 bottle | 16729-415-17 | Accord HealthcareIndia | 10 July 2017 |
| 100 tablet in 1 bottle | 59651-895-01 | Aurobindo PharmaIndia | 1 March 2024 |
| 1000 tablet in 1 bottle | 59651-895-99 | Aurobindo PharmaIndia | 1 March 2024 |
| 100 tablet in 1 bottle | 23155-095-01 | Avet PharmaceuticalsIndia | 13 February 2018 |
| 100 tablet in 1 bottle | 29300-354-01 | Unichem LaboratoriesIndia | 15 March 2024 |
| 1000 tablet in 1 bottle | 29300-354-10 | Unichem LaboratoriesIndia | 15 March 2024 |
| 30 tablet in 1 bottle | 29300-354-13 | Unichem LaboratoriesIndia | 15 March 2024 |
| 100 tablet in 1 bottle | 59762-1391-7 | Mylan Pharmaceuticals | 3 August 2026 |
| 100 tablet in 1 bottle | 59762-2480-7 | Mylan Pharmaceuticals | 19 October 2021 |
| 100 tablet in 1 bottle | 60505-0096-0 | Apotex | 14 July 2011 |
| 1000 tablet in 1 bottle | 60505-0096-1 | Apotex | 14 July 2011 |
| 90 tablet in 1 bottle | 62135-054-90 | Chartwell RX | 6 June 2023 |
| 100 tablet in 1 bottle | 16571-168-01 | Rising Pharma Holdings | 20 May 2024 |
| 100 tablet in 1 bottle | 0093-2067-01 | Teva Pharmaceuticals | 6 December 2014 |
| 100 tablet in 1 bottle | 0832-1359-11 | Upsher-Smith laboratories | 17 April 2018 |
| 6000 tablet in 1 bottle | 71610-160-16 | Aphena Pharma Solutions - Tennessee | 20 September 2018 |
| 90 tablet in 1 bottle | 71610-160-60 | Aphena Pharma Solutions - Tennessee | 23 November 2021 |
| 90 tablet in 1 bottle | 71610-628-60 | Aphena Pharma Solutions - Tennessee | 13 December 2021 |
| 60 tablet in 1 bottle | 71610-831-53 | Aphena Pharma Solutions - Tennessee | 13 May 2024 |
| 90 tablet in 1 bottle | 71610-831-60 | Aphena Pharma Solutions - Tennessee | 13 May 2024 |
| 90 tablet in 1 bottle | 71610-878-60 | Aphena Pharma Solutions - Tennessee | 13 February 2025 |
| 180 tablet in 1 bottle | 71610-878-80 | Aphena Pharma Solutions - Tennessee | 13 February 2025 |
| 30 tablet in 1 bottle | 50090-3143-0 | A-S Medication Solutions | 28 October 2021 |
| 100 tablet in 1 bottle | 50090-3143-1 | A-S Medication Solutions | 27 September 2017 |
| 100 tablet in 1 bottle | 42291-260-01 | AvKARE | 9 April 2015 |
| 50 blister pack in 1 box / 1 tablet in 1 blister pack | 50268-225-15 | AvPAK | 9 May 2022 |
| 100 tablet in 1 bottle | 84677-047-01 | Golden State Medical Supply | 11 May 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 2 November 1990 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Doxazosin 8 mg tablet.
Other strengths and forms of Doxazosin
Clinical summary
Doxazosin is an alpha-adrenergic blocker indicated for signs and symptoms of Benign Prostatic Hyperplasia (BPH), among other approved uses. It is available as tablets and extended-release tablets for oral use. MedsAcross supplies Doxazosin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DoxazosinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Doxazosin mesylate prescribing information (Mylan Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Doxazosin 8 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.